Abstract
Get full access to this article
View all access options for this article.
References
1.
Akouos. Akouos Receives FDA Clearance of its IND application for AK-OTOF, a gene therapy intended for the treatment of OTOF-mediated hearing loss. September 13, 2022. https://investors.akouos.com/news-releases/news-release-details/akouos-receives-fda-clearance-its-ind-application-ak-otof-gene (last accessed
September 14 , 2022
).
2.
Immusoft. Immusoft announces FDA clearance of IND application for ISP-001 for MPS I, the first engineered B cell therapy to enter into clinical trials. September 1, 2022. https://www.immusoft.com/2022/09/01/immusoft-announces-fda-clearance-of-ind-application-for-isp-001-for-mps-i-the-first-engineered-b-cell-therapy-to-enter-into-clinical-trials/ (last accessed
September 12 , 2022
).
3.
bluebird bio. bluebird bio announces FDA approval of ZYNTEGLO®, the first gene therapy for people with beta-thalassemia who require regular red blood cell transfusions. August 17, 2022. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-zynteglor-first-gene-therapy (last accessed
September 12 , 2022
).
4.ElevateBio . ElevateBio and the University of Pittsburgh announce creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to accelerate cell and gene therapy innovation. https://www.elevate.bio/press-releases/elevatebio-and-the-university-of-pittsburgh-announce-creation-of-pitt-bioforge-biomanufacturing-center-at-hazelwood-green-to-accelerate-cell-and-gene-therapy-innovation (last accessed
September 12 , 2022
).
5.Forge Biologics. Forge Biologics announces $90 million series C financing to expand client offerings and add services to enhance end-to-end gene therapy manufacturing platforms . September 12, 2022. https://www.forgebiologics.com/2022/09/12/forge-biologics-announces-90-million-series-c-financing-to-expand-client-offerings-and-add-services-to-enhance-end-to-end-gene-therapy-manufacturing-platforms/ (last accessed
September 12 , 2022
).
6.
U.S. Securities and Exchange Commission. Form 8-K, BioMarin Pharmaceutical, Inc. September 12, 2022. https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000119312522242460/d306559d8k.htm (last accessed
September 12 , 2022
).
7.
Charles River Laboratories International and Cure AP-4. Charles River and Cure AP-4 announce gene therapy manufacturing collaboration. September 6, 2022. https://ir.criver.com/news-releases/news-release-details/charles-river-and-cure-ap-4-announce-gene-therapy-manufacturing (last accessed
September 12 , 2022
).